Glutamergic agents may one day be used as a novel treatment for mood and anxiety disorders, new research presented at the 26th ECNP Congress suggests. "Our results suggest the glutamatergic system is a truly viable target for antidepressant Profug development," says Professor Gerard Sanacora, from the Yale School of Medicine, Connecticut, US...
-
Source: http://www.medicalnewstoday.com/releases/267109.php
--
Manage subscription | Powered by rssforward.com
09 Oct, 2013
-
Source: http://www.medicalnewstoday.com/releases/267109.php
--
Manage subscription | Powered by rssforward.com
Post a Comment